CJC-1295 + GHRP-6 Research Blend Long-Acting GHRH Analogue + GHS-R1a/CD36 Agonist · Dual GH Axis Research · ≥99% HPLC · Janoshik COA
CJC-1295 (DAC-modified GHRH analogue) and GHRP-6 (hexapeptide GHS-R1a/CD36 agonist) combine GHRH-R and ghrelin receptor activation for maximal GH release in preclinical research. Unlike Ipamorelin, GHRP-6 also stimulates appetite via ghrelin pathway — making this combination relevant to cachexia, caloric deficit, and body composition research beyond standard somatropause studies. QSC stocks both at ≥99% HPLC with Janoshik independent COA.
CJC-1295 (DAC-modified GHRH analogue) + GHRP-6 (hexapeptide GHS-R1a/CD36 agonist) combines independent GH axis receptor activation for additive GH release in research models. GHRP-6 differs from Ipamorelin in also activating the appetite-stimulating CD36 pathway via ghrelin — relevant for cachexia and caloric deficit research. QSC stocks both at ≥99% HPLC with Janoshik COA.
What is the difference between GHRP-6 and Ipamorelin?
Both are GHS-R1a agonists but with different selectivity profiles. Ipamorelin is the most selective — zero cortisol, zero prolactin, zero ACTH elevation. GHRP-6 also activates CD36 (ghrelin appetite pathway) and produces moderate cortisol and prolactin elevation. GHRP-6 produces higher total GH release but less hormonal specificity. Research context determines which is appropriate.
Buy CJC-1295 + GHRP-6 Research Blend Components
Both compounds available at ≥99% HPLC · Janoshik Independent COA · verify.janoshik.com
Research Use Only: All QSC products sold strictly for in vitro laboratory research. Not for human or veterinary use. Information on this page is educational and does not constitute medical advice.
